{"id":"W2982194168","doi":"10.1093/eurheartj/ehz745.1159","title":"P4783Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Rivaroxaban; Apixaban; Edoxaban; Discontinuation; Dabigatran; Internal medicine; Hazard ratio; Atrial fibrillation; Dosing; Proportional hazards model; Vitamin K antagonist; Confidence interval; Warfarin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01503529,0.0007362654,0.002271751,0.0005191806,0.000545346,0.001961624,0.0009381715,0.0008699379,0.003685784],"category_scores_gemma":[0.01227232,0.0004992247,0.006819568,0.001117707,0.000523244,0.001324638,0.0009130664,0.002169756,0.0008435389],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006584022,"about_ca_system_score_gemma":0.001841523,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001430332,"about_ca_topic_score_gemma":0.001768665,"domain_scores_codex":[0.9937469,0.003016148,0.0006395883,0.001048201,0.0008924516,0.000656704],"domain_scores_gemma":[0.9867373,0.003983492,0.005189574,0.002455476,0.001069054,0.0005651778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1871408,0.003436246,0.6617579,0.001406183,0.04429354,0.0003887483,0.0002821318,0.009298203,0.002556791,0.0009104482,0.02767851,0.0608505],"study_design_scores_gemma":[0.0463,0.03430477,0.8342868,0.0004117589,0.04401148,0.0008412423,0.0002659808,0.01291688,0.005053682,0.002298564,0.01908292,0.0002259554],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9363279,0.004564002,0.006678035,0.0008507221,0.0001813651,0.001411102,0.04435146,0.0002074252,0.005427966],"genre_scores_gemma":[0.9608188,0.0005699389,0.002031199,0.0006608495,0.00009481189,0.001587091,0.03264282,0.00006146038,0.001533011],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01503529,"threshold_uncertainty_score":0.07951516,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.154994027036143,"score_gpt":0.3680220682579905,"score_spread":0.2130280412218475,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}